Plain-English translation of NCT06801002 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is one of the first times this treatment has been tested in people.
This is an early-stage trial (Phase 1) testing a new drug called in patients with advanced solid tumors or certain blood cancers (lymphomas) that have stopped responding to standard treatments. Researchers want to understand how safe the medication is, what side effects it causes, and whether it shows any ability to help shrink tumors. The study starts with small doses and gradually increases them to find the safest and most effective dose.
Many patients with advanced cancers run out of standard treatment options that work. This medication targets a new pathway in cancer cells, so it may help people who haven't benefited from existing therapies or can no longer tolerate them.
You likely qualify if…
You likely don't qualify if…
You would take the medication by mouth (as a pill) once daily, starting at a low dose. The first group of participants will take a single dose and then have a week off to see how your body handles the drug. After that, patients take the medication continuously until their cancer worsens or side effects become too difficult. Researchers will monitor you closely with blood tests, scans, and check-ins to watch for side effects and signs of benefit. Depending on which dose group you join, the study may last several months or longer if the medication is helping your cancer.
AI-generated summary from trial data · Jul 21, 2026 · Not medical advice
United States